Bioventix PLC manufactures and supplies sheep monoclonal antibodies (SMAs) for use in blood-testing machines in hospitals and other labs worldwide.
No risks detected for 51B from our risk checks.
Flawless balance sheet with solid track record and pays a dividend.
Share Price & News
How has Bioventix's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 51B has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 51B exceeded the German Biotechs industry which returned -3.2% over the past year.
Return vs Market: 51B exceeded the German Market which returned 3.8% over the past year.
Price Volatility Vs. Market
How volatile is Bioventix's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Bioventix undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 51B (€44) is trading above our estimate of fair value (€18.57)
Significantly Below Fair Value: 51B is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 51B is good value based on its PE Ratio (31.2x) compared to the XE Biotechs industry average (40.9x).
PE vs Market: 51B is poor value based on its PE Ratio (31.2x) compared to the German market (20.9x).
Price to Earnings Growth Ratio
PEG Ratio: 51B is poor value based on its PEG Ratio (6x)
Price to Book Ratio
PB vs Industry: 51B is overvalued based on its PB Ratio (21.1x) compared to the DE Biotechs industry average (2.3x).
How is Bioventix forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 51B's forecast earnings growth (5.2% per year) is above the savings rate (0.2%).
Earnings vs Market: 51B's earnings (5.2% per year) are forecast to grow slower than the German market (23.4% per year).
High Growth Earnings: 51B's earnings are forecast to grow, but not significantly.
Revenue vs Market: 51B's revenue (7.3% per year) is forecast to grow faster than the German market (5.9% per year).
High Growth Revenue: 51B's revenue (7.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 51B's Return on Equity is forecast to be high in 3 years time
How has Bioventix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 51B has high quality earnings.
Growing Profit Margin: 51B's current net profit margins (65.3%) are higher than last year (63.3%).
Past Earnings Growth Analysis
Earnings Trend: 51B's earnings have grown significantly by 20% per year over the past 5 years.
Accelerating Growth: 51B's earnings growth over the past year (17.1%) is below its 5-year average (20% per year).
Earnings vs Industry: 51B earnings growth over the past year (17.1%) exceeded the Biotechs industry -1.4%.
Return on Equity
High ROE: 51B's Return on Equity (67.5%) is considered outstanding.
How is Bioventix's financial position?
Financial Position Analysis
Short Term Liabilities: 51B's short term assets (£9.4M) exceed its short term liabilities (£940.2K).
Long Term Liabilities: 51B's short term assets (£9.4M) exceed its long term liabilities (£63.0K).
Debt to Equity History and Analysis
Debt Level: 51B is debt free.
Reducing Debt: 51B has not had any debt for past 5 years.
Debt Coverage: 51B has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 51B has no debt, therefore coverage of interest payments is not a concern.
What is Bioventix current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 51B's dividend (3.17%) is higher than the bottom 25% of dividend payers in the German market (1.25%).
High Dividend: 51B's dividend (3.17%) is low compared to the top 25% of dividend payers in the German market (3.83%).
Stability and Growth of Payments
Stable Dividend: 51B's dividends per share have been stable in the past 10 years.
Growing Dividend: 51B's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (62.1%), 51B's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Peter Harrison (62 yo)
Mr. Peter John Harrison, MA, serves as the Chief Executive Officer of Bioventix PLC. Mr. Harrison has worked in the field of antibody technology since 1986 and has extensive experience of the development a ...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD423.24K) is below average for companies of similar size in the German market ($USD758.05K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
|CEO & Director||no data||UK£322.13k||8% |
|Finance Director & Non-Executive Director||no data||UK£4.28k||no data|
|CFO & Director||0.083yr||no data||no data|
|Independent Non-Executive Chairman||15.75yrs||UK£27.54k||0.30% |
|Independent Non-Executive Director||6.58yrs||UK£23.41k||no data|
Experienced Board: 51B's board of directors are considered experienced (6.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bioventix PLC's company bio, employee growth, exchange listings and data sources
- Name: Bioventix PLC
- Ticker: 51B
- Exchange: DB
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£207.071m
- Listing Market Cap: UK£229.976m
- Shares outstanding: 5.21m
- Website: https://www.bioventix.com
Number of Employees
- Bioventix PLC
- 27-28 Eastcastle Street
- Greater London
- W1W 8DH
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BVXP||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Apr 2010|
|51B||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Apr 2010|
Bioventix PLC manufactures and supplies sheep monoclonal antibodies (SMAs) for use in blood-testing machines in hospitals and other labs worldwide. The company offers a portfolio of purified SMAs for thyro ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/02 21:12|
|End of Day Share Price||2020/07/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.